This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of
the study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and
second, to explore neurobiological mechanisms of action of guanfacine.
Subject population is comprised of 100 persons with PTSD. 50 patients will receive
guanfacine and 50 patients will receive a placebo. Guanfacine is prescribed at 1 mg/day and
may be increased to 2 mg/day. Samples of plasma MHPG will be collected weekly. Clinical
ratings of PTSD anxiety and depression, as well as vital signs, will be assessed weekly.
Repeated measures analysis of variance will assess significance of main effect of drug,
time, and drug by time.
- Males and females, age 18-65
- Diagnosis of PTSD from combat or civilian trauma
- No major medical problems such as diabetes, cardiovascular disease
- Taking no psychiatric medication, or taking only one SSRI antidepressant